On May 15th, Gizcoupon reported that Huawei Yu Chengdong’s official Weibo account(Chinese Social Platform) announced that its smartwatch would be the first to support Hyperglycemia risk assessment research. The Huawei WATCH 4 series will be the first to support this feature. Users can opt to participate in the research project and wear the watch for a period of time. The watch will then inform them of their Hyperglycemia risk level, thereby encouraging them to pay further attention to their health and lifestyle. The Huawei WATCH 4 series will debut at Huawei’s new product launch on May 18th, Beijing time.
As shown on the poster, the product is not a medical device, and the measured data and results are for reference only and should not be used as a basis for diagnosis and treatment. The Hyperglycemia risk assessment feature requires users to participate in blood sugar health research initiated by third-party professional medical institutions. In addition, it is unsuitable for users under 18 years of age, those with type I diabetes, gestational diabetes, and other special types of diabetes. Using the picture as an example, a Hyperglycemia risk assessment can assess the type of risk within a week. For example, for medium risk, “there may be short-term fluctuations in blood sugar, and excessive intake of high-sugar, high-oil, and high-fat diets may increase the risk of Hyperglycemia.” Furthermore, users can also click the button to “start a new round of assessment.”
Previously, at a European launch event, Huawei unveiled its flagship smartwatch, the WATCH 4 series, as reported by Gizcoupon. The Huawei WATCH 4 Pro features a 48mm titanium case, a 1.5-inch LTPO AMOLED display with a sapphire glass cover, and a weight of 48 grams. In contrast, the Huawei WATCH 4 is slightly smaller, with a 46mm stainless steel case.
